Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience

Ofer Purim*, Alexander Beny, Moshe Inbar, Katerina Shulman, Baruch Brenner, Elizabeth Dudnik, Felix Bokstein, Mark Temper, Dror Limon, Diana Matceyevsky, David Sarid, Amiel Segal, Valeriya Semenisty, Ronen Brenner, Tamar Peretz, Efraim Idelevich, Sharon Pelles-Avraham, Amichay Meirovitz, Arie Figer, Kenneth RussellAndreas Voss, Addie Dvir, Lior Soussan-Gutman, Ayala Hubert

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: Precision treatment of cancer uses biomarker-driven therapy to individualize and optimize patient care. Objective: To evaluate real-life clinical experience with biomarker-driven therapy in metastatic gastric and esophageal cancer in Israel. Patients and Methods: This multicenter retrospective cohort study included patients with metastatic gastric or esophageal cancer who were treated in the participating institutions and underwent biomarker-driven therapy. Treatment was considered to have a benefit if the ratio between the longest progression-free survival (PFS) post biomarker-driven therapy and the last PFS before the biomarker-driven therapy was ≥1.3. The null hypothesis was that ≤15% of patients gain such benefit. Results: The analysis included 46 patients (61% men; median age, 58 years; 57% with poorly-differentiated tumors). At least one actionable (i.e., predictive of response to a specific therapy) biomarker was identified for each patient. Immunohistochemistry was performed on all samples and identified 1–8 (median: 3) biomarkers per patient (most commonly: low TS, high TOPO1, high TOP2A). Twenty-eight patients received therapy after the biomarker analysis (1–4 lines). In the 1st line after biomarker analysis, five patients (18%) achieved a partial response and five (18%) stable disease; the median (range) PFS was 129 (12–1155) days. Twenty-four patients were evaluable for PFS ratio analysis; in seven (29.2%), the ratio was ≥1.3. In a one-sided exact binomial test vs. the null hypothesis, p = 0.019; therefore, the null hypothesis was rejected. Conclusions: Our findings demonstrated that implementing biomarker-driven analysis is feasible and could provide clinical benefit for a considerable proportion (~30%) of patients with metastatic gastric or esophageal cancer.[Figure not available: see fulltext.].

Original languageEnglish
Pages (from-to)217-226
Number of pages10
JournalTargeted Oncology
Issue number2
StatePublished - 1 Apr 2018


FundersFunder number
Avital Bareket-Samish
Caris Life Sciences
Teva Pharmaceutical Industries


    Dive into the research topics of 'Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience'. Together they form a unique fingerprint.

    Cite this